Bempedoic acid: what prospective uses?
| Autor: | Jacomelli I; Department of Cardiology, Policlinico Casilino, Via Casilina 1049, 00169 Rome, Italy., Monzo L; Department of Cardiology, Policlinico Casilino, Via Casilina 1049, 00169 Rome, Italy.; Centre d'investigation Cliniques Plurithématique, Universitè de Lorraine INSERM, Nancy, France., Panattoni G; Department of Cardiology, Policlinico Casilino, Via Casilina 1049, 00169 Rome, Italy., Lanzillo C; Department of Cardiology, Policlinico Casilino, Via Casilina 1049, 00169 Rome, Italy., Rebecchi M; Department of Cardiology, Policlinico Casilino, Via Casilina 1049, 00169 Rome, Italy., Calò L; Department of Cardiology, Policlinico Casilino, Via Casilina 1049, 00169 Rome, Italy. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | European heart journal supplements : journal of the European Society of Cardiology [Eur Heart J Suppl] 2023 Apr 26; Vol. 25 (Suppl C), pp. C109-C111. Date of Electronic Publication: 2023 Apr 26 (Print Publication: 2023). |
| DOI: | 10.1093/eurheartjsupp/suad012 |
| Abstrakt: | There is still the need to lower LDL-c, although the use of statins, ezetimibe and proprotein convertase subtilisin/kexin type 9. Patients with atherosclerotic cardiovascular disease and/or familial hypercholesterolaemia are treated with statins at maximum tolerated dose, with or without further lipid-lowering drugs, but very often, we can't reach the goal, so bempedoic acid treatment lead to a significant reduction in low-density lipoprotein cholesterol, in different groups of patients, with a favourable safety profile. Competing Interests: Conflict of interest: None declared. (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|